Physicians' Academy for Cardiovascular Education

Large pooled analysis reveals no safety concerns with PCSK9-inhibitor

June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson




Jennifer Robinson (University of Iowa, Iowa City, IA, USA)
Recorded at ISA2015, Amsterdam, The Netherlands on May 24-26, 2015
 
ISA2015 | Clinical Breakthroughs In a pooled analysis of 14 trials with PCSK9-inhibitor alirocumab, in over 5000 patients who achieved LDL <25 of <15 mg/dL, followed for up to 2 years, no safety signals were observed.